The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern

被引：43

作者：

Currie, C. J. ^{[1
]}

Johnson, J. A. ^{[2
]}

机构：

[1] Cardiff Univ, Sch Med, Cardiff, S Glam, Wales

[2] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada

来源：

DIABETES OBESITY & METABOLISM | 2012年 / 14卷 / 01期

关键词：

insulin; pharmacovigilance; review; safety; type; 2; diabetes; GLYCEMIC CONTROL; CANCER-RISK; MELLITUS; GLUCOSE; DISEASE; MORTALITY; THERAPY; TRIAL; TIME; METAANALYSIS;

D O I：

10.1111/j.1463-1326.2011.01469.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There is no doubt about the value of exogenous insulin for people with type 1 diabetes. The purpose of this commentary is to discuss emerging evidence that this may not be the case for the majority of people with type 2 diabetes.

引用

页码：1 / 4

页数：4

共 41 条

[1] Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial - Veterans Affairs Cooperative Study on gylcemic control and complications in type II diabetes
Abraira, C
Colwell, J
Nuttall, F
Sawin, CT
Henderson, W
Comstock, JP
Emanuele, NV
Levin, SR
Pacold, I
Lee, HS
Silbert, CK
Cxypoliski, R
Vasquez, M
Kernan, D
Niewoehner, C
Backes, M
Bradley, M
Bradley, M
Crow, R
Rubino, F
Bushnell, D
Pfeifer, M
Service, FJ
Howard, B
Chew, E
Hoogwerf, B
Seigel, D
Clark, CM
Olefsky, JM
Porte, D
Sussman, KE
Johnson, N
Christine, B
Tir, K
Sather, M
Day, P
Morgan, N
Deykin, D
Gold, J
Huang, P
[J]. ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (02) : 181 - 188
[2] Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S011, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc12-s011]
[3] Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart
Anselmino, Matteo
Oehrvik, John
Malmberg, Klas
Standl, Eberhard
Ryden, Lars
[J]. EUROPEAN HEART JOURNAL, 2008, 29 (02) : 177 - 184
[4] Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: A case-control study in Northern Italy
Bonelli, L
Aste, H
Bovo, P
Cavallini, G
Felder, M
Gusmaroli, R
Morandini, E
Ravelli, P
Briglia, R
Lombardo, L
De Micheli, A
Pugliese, V
[J]. PANCREAS, 2003, 27 (02) : 143 - 149
[5] Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure
Bowker, S. L.
Yasui, Y.
Veugelers, P.
Johnson, J. A.
[J]. DIABETOLOGIA, 2010, 53 (08) : 1631 - 1637
[6] Cao Wenhong, 2011, Curr Mol Pharmacol, V4, P154
[7] A1C and Cardiovascular Outcomes in Type 2 Diabetes A nested case-control study
Colayco, Danielle C.
Niu, Fang
McCombs, Jeffrey S.
Cheetham, T. Craig
[J]. DIABETES CARE, 2011, 34 (01) : 77 - 83
[8] The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J.
Poole, C. D.
Gale, E. A. M.
[J]. DIABETOLOGIA, 2009, 52 (09) : 1766 - 1777
[9] Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
Currie, Craig J.
Peters, John R.
Tynan, Aodan
Evans, Marc
Heine, Robert J.
Bracco, Oswaldo L.
Zagar, Tony
Poole, Chris D.
[J]. LANCET, 2010, 375 (9713) : 481 - 489
[10] Donadon Valter, 2009, Expert Rev Gastroenterol Hepatol, V3, P465, DOI 10.1586/egh.09.41

← 1 2 3 4 5 →